Marcel H A M Fens
Overview
Explore the profile of Marcel H A M Fens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ecker V, Brandmeier L, Stumpf M, Giansanti P, Moreira A, Pfeuffer L, et al.
Cell Rep
. 2023 Oct;
42(10):113017.
PMID: 37792532
Despite available targeted treatments for the disease, drug-resistant chronic lymphocytic leukemia (CLL) poses a clinical challenge. The objective of this study is to examine whether the dual-specific phosphatases DUSP1 and...
2.
Swart L, Fens M, van Oort A, Waranecki P, Mata Casimiro L, Tuk D, et al.
Pharmaceutics
. 2023 Jun;
15(6).
PMID: 37376052
Lipid nanoparticles (LNPs) have evolved rapidly as promising delivery systems for oligonucleotides, including siRNAs. However, current clinical LNP formulations show high liver accumulation after systemic administration, which is unfavorable for...
3.
van Vliet E, Knol M, Schiffelers R, Caiazzo M, Fens M
J Control Release
. 2023 Jun;
360:212-224.
PMID: 37343725
Parkinson's disease (PD) is a neurodegenerative disorder characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) resulting in dopamine (DA) deficiency, which manifests itself in motor...
4.
Mesquita B, Fens M, Di Maggio A, Bosman E, Hennink W, Heger M, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499301
Nanoparticles (NPs) are commonly modified with tumor-targeting moieties that recognize proteins overexpressed on the extracellular membrane to increase their specific interaction with target cells. Nanobodies (Nbs), the variable domain of...
5.
Bevers S, Kooijmans S, Van de Velde E, Evers M, Seghers S, Gitz-Francois J, et al.
Mol Ther
. 2022 Jul;
30(9):3078-3094.
PMID: 35821637
mRNA vaccines have recently proved to be highly effective against SARS-CoV-2. Key to their success is the lipid-based nanoparticle (LNP), which enables efficient mRNA expression and endows the vaccine with...
6.
Varela-Moreira A, van Leur H, Krijgsman D, Ecker V, Braun M, Buchner M, et al.
Int J Pharm
. 2022 Mar;
618:121638.
PMID: 35257802
In the present work, we aim at developing an in vitro release assay to predict circulation times of hydrophobic drugs loaded into polymeric micelles (PM), upon intravenous (i.v.) administration. PM...
7.
Mashayekhi V, Mocellin O, Fens M, Krijger G, Brosens L, Oliveira S
Theranostics
. 2021 Sep;
11(18):9022-9037.
PMID: 34522225
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal types of cancer due to the relatively late diagnosis and the limited therapeutic options. Current treatment regimens mainly comprise the...
8.
Liu Y, Fens M, Capomaccio R, Mehn D, Scrivano L, Kok R, et al.
J Control Release
. 2020 Oct;
328:942-951.
PMID: 33098910
Polymeric micelles are extensively investigated as drug delivery systems for hydrophobic drugs including photosensitizers (PSs). In order to benefit from micelles as targeted delivery systems for PS, rather than only...
9.
Deshantri A, Fens M, Ruiter R, Metselaar J, Storm G, Mandhane S, et al.
Hemasphere
. 2020 Sep;
4(5):e463.
PMID: 32923984
No abstract available.
10.
Patras L, Fens M, Vader P, Barendrecht A, Sesarman A, Banciu M, et al.
Int J Mol Sci
. 2020 Aug;
21(17).
PMID: 32824972
Extracellular vesicles (EV) secreted in the tumour microenvironment (TME) are emerging as major antagonists of anticancer therapies by orchestrating the therapeutic outcome through altering the behaviour of recipient cells. Recent...